NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib

• Published in: Oxidative medicine and cellular longevity Vol. 2017; no. 2017; pp. 1 - 19
• Main Authors: Bown, James, Moult, Peter R., Langdon, Simon P., Khalil, Hilal S., Kankia, Ibrahim H., Deeni, Yusuf Y.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Adapter proteins; Antimitotic agents; Antineoplastic agents; Antioxidants; Breast cancer; Cancer; Cancer cells; Cancer therapies; Care and treatment; Cytotoxicity; Dermatology; Genetic transcription; Health aspects; Kinases; Lymphoma; Medical research; Metabolism; Ovarian cancer; Phenols; Rodents; Signal transduction; Studies; Targeted cancer therapy; United Kingdom
• ISSN: 1942-0900; 1942-0994
• DOI: 10.1155/2017/1864578

NF-E2-related factor 2 (NRF2) regulates the transcription of a battery of metabolic and cytoprotective genes. NRF2 and epidermal growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and progression. NRF2 and HERs confer cancers with resistance to several therapeutic agents. Nevertheless, there is limited understanding of the regulation of HER expression and activation and the link between NRF2 and HER signalling pathways. We show that NRF2 regulates both basal and inducible expression of HER1, as treatment of ovarian cancer cells (PEO1, OVCAR3, and SKOV3) with NRF2 activator tBHQ inducing HER1, while inhibition of NRF2 by siRNA knockdown or with retinoid represses HER1. Furthermore, treatment of cells with tBHQ increased total and phosphorylated NRF2, HER1, and AKT levels and compromised the cytotoxic effect of lapatinib or erlotinib. Treatment with siRNA or retinoid antagonised the effect of tBHQ on NRF2 and HER1 levels and enhanced the sensitivity of ovarian cancer cells to lapatinib or erlotinib. Pharmacological or genetic inhibition of NRF2 and/or treatment with lapatinib or erlotinib elevated cellular ROS and depleted glutathione. This extends the understanding of NRF2 and its regulation of HER family receptors and opens a strategic target for improving cancer therapy.